









Markets
/
Stocks
/
nasdaq-bivi
/

BioVie Inc

BIVI

1.130USD

+0.070+6.60%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

8.52MMarket Cap

LossP/E TTM



BioVie Inc

1.130

+0.070+6.60%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of BioVie Inc

Currency: USD Updated: 2026-02-06

Key Insights

BioVie Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 195 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as , with the highest price target at 12.00.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

BioVie Inc's Score

Industry at a Glance

Industry Ranking

195 / 392

Overall Ranking

375 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

BioVie Inc Highlights

StrengthsRisks

BioVie Inc. is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. In neurodegenerative disease, the Company's drug candidate bezisterim inhibits inflammatory activation of extracellular signal-regulated kinase and the transcription factor nuclear factor-kB, and the associated neuroinflammation and insulin resistance, but not ERK and NFkB homeostatic functions (such as insulin signaling and neuron growth and survival). Both neuroinflammation and insulin resistance are drivers of Alzheimer’s disease (AD) and Parkinson’s disease (PD). Persistent systematic inflammation and neuroinflammation are key features in patients with neurological symptoms of long COVID. In liver disease, the Company's orphan drug candidate BIV201, is being evaluated for Phase III clinical testing for the reduction of further decompensation in participants with liver cirrhosis and ascites.

Overvalued

The company’s latest PE is -0.18, at a high 3-year percentile range.

Held by The Vanguard

Star Investor The Vanguard holds 213.53K shares of this stock.

Analyst Rating

Based on 0 analysts

Current Rating

12.000

Target Price

+867.74%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of BioVie Inc is 6.89, ranking 189 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.89

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.68

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

BioVie Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of BioVie Inc is 7.49, ranking 114 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.18, which is -58.73% below the recent high of -0.08 and -5865.55% above the recent low of -11.03.

Score

Industry at a Glance

Previous score

7.49

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 195/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of BioVie Inc is 8.00, ranking 164 out of 392 in the Biotechnology & Medical Research industry. The average price target is 12.00, with a high of 12.00 and a low of 12.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of BioVie Inc is 2.07, ranking 380 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 1.29 and the support level at 1.01, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

2.07

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(2)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.008

Sell

RSI(14)

41.686

Neutral

STOCH(KDJ)(9,3,3)

24.241

Neutral

ATR(14)

0.090

High Vlolatility

CCI(14)

-134.555

Sell

Williams %R

70.833

Sell

TRIX(12,20)

-0.502

Sell

StochRSI(14)

54.231

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

1.156

Sell

MA10

1.183

Sell

MA20

1.206

Sell

MA50

1.328

Sell

MA100

1.543

Sell

MA200

4.418

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of BioVie Inc is 3.00, ranking 197 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 5.72%, representing a quarter-over-quarter decrease of 1.70%. The largest institutional shareholder is The Vanguard, holding a total of 213.53K shares, representing 2.83% of shares outstanding, with 2.63% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Diametric Capital

370.00K

The Vanguard Group, Inc.

Star Investors

128.93K

+133.42%

Prelude Capital Management, LLC

144.76K

Prosperity Wealth Management, Inc.

143.50K

Palos Management Inc.

125.00K

Citadel Advisors LLC

104.53K

The Philadelphia Trust Company

75.01K

Renaissance Technologies LLC

Star Investors

72.92K

Geode Capital Management, L.L.C.

52.37K

+275.71%

Squarepoint Capital LLP

33.29K

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. No risk assessment score is currently available for BioVie Inc. The Biotechnology & Medical Research industry's average is 3.38. The company's beta value is 0.56. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.